BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12879604)

  • 1. [Molecular-biological markers as prognostic factors in breast cancer of I-IIA stage].
    Stepanova EV; Zagrekova EI; Ermilova VD; Turbin AD; Petrovichev NN; Vysotskaia IV; Dbar ZhN; Pashchenko NV; Baryshnikov AIu; Lichinitser MR
    Arkh Patol; 2003; 65(3):14-8. PubMed ID: 12879604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin expression and survival in human breast cancer.
    Berry MG; Gui GP; Wells CA; Carpenter R
    Eur J Surg Oncol; 2004 Jun; 30(5):484-9. PubMed ID: 15135474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.
    Grönberg M; Fjällskog ML; Jirström K; Janson ET
    Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
    Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A
    Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Importance of PCNA proliferating fraction and histomorphologic prognostic factors for survival in breast cancer].
    Schönborn I; Minguillon C; Möhner M; Ebeling K
    Pathologe; 1993 Dec; 14(6):307-12. PubMed ID: 7907179
    [No Abstract]   [Full Text] [Related]  

  • 9. [Expression of the genes FHIT, Bcl-2 and Bax in breast infiltrating ductal carcinoma and clinicopathological significance thereof].
    Wang ZB; Zhao P; Liu M; Li XH
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(31):2171-6. PubMed ID: 17064501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of prognostic significance of nm23 expression in human primary breast cancer.
    Göhring UJ; Eustermann I; Becker M; Neuhaus W; Rein DT; Schöndorf T
    Oncol Rep; 2002; 9(6):1205-8. PubMed ID: 12375020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. StatBite: Breast cancer: 5-year survival rates in U.S. for selected histologic types by stage.
    J Natl Cancer Inst; 2009 Oct; 101(19):1303. PubMed ID: 19755678
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
    Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L
    Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The labelling index as a prognostic marker in breast carcinoma].
    Bisail M; Nieddu S; Sarobba MG; Sanna G; Milia V; Ghì MG; Farris A
    Minerva Med; 1994 Apr; 85(4):141-4. PubMed ID: 8028740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD24 expression has a prognostic impact in breast carcinoma.
    Athanassiadou P; Grapsa D; Gonidi M; Athanassiadou AM; Tsipis A; Patsouris E
    Pathol Res Pract; 2009; 205(8):524-33. PubMed ID: 19243896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor location of the lower-inner quadrant is associated with an impaired survival for women with early-stage breast cancer.
    Sarp S; Fioretta G; Verkooijen HM; Vlastos G; Rapiti E; Schubert H; Sappino AP; Bouchardy C
    Ann Surg Oncol; 2007 Mar; 14(3):1031-9. PubMed ID: 17176985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
    Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
    Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters.
    Qureshi HS; Linden MD; Divine G; Raju UB
    Am J Clin Pathol; 2006 Mar; 125(3):377-85. PubMed ID: 16613340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series.
    Viale G; Rotmensz N; Maisonneuve P; Orvieto E; Maiorano E; Galimberti V; Luini A; Colleoni M; Goldhirsch A; Coates AS
    Breast Cancer Res Treat; 2009 Sep; 117(1):211-4. PubMed ID: 18629634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
    Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.